Needham Reiterates Buy on Heron Therapeutics, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a Buy rating on Heron Therapeutics (NASDAQ:HRTX) and maintained a $5 price target.
May 16, 2024 | 9:30 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Serge Belanger has reiterated a Buy rating on Heron Therapeutics and maintained a $5 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and the maintenance of a $5 price target by a reputable analyst suggests a positive outlook for Heron Therapeutics. This could lead to increased investor confidence and a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100